Vimarsana
Biggest News Aggregation in the World

Page 8 - Transition Report News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Transition Report. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Transition Report Today - Breaking & Trending Today

Chicago's Impending Hellscape Is A 'Blueprint' For the Left's National Dreams - Vimarsana News

Chicago's Impending Hellscape Is A 'Blueprint' For the Left's National Dreams

Chicagoans cheered when former Mayor Lori Lightfoot's re-election campaign crashed and burned earlier this year.

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma - Vimarsana News

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

First patient with MC1R-positive metastatic melanoma treated with 212Pb-VMT01Preliminary data readout from dose escalation study expected Q4 2023 RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 ... -August 11, 2023 at 08:06 am- MarketScreener

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment - Vimarsana News

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 -- Perspective Therapeutics, Inc.  , a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents...

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique ... - Vimarsana News

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique ...

RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary

BRISTOW GROUP REPORTS SECOND QUARTER 2023 RESULTS - Vimarsana News

BRISTOW GROUP REPORTS SECOND QUARTER 2023 RESULTS

Total revenues of $319.4 million in Q2 2023 compared to $302.0 million in Q1 2023 Net loss of $1.6 million, or $0.06 per diluted share, in Q2 2023 compared to...